Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Synthetic and Clinical Perspectives of Evotaz: An Overview

Author(s): Sachin Puri, Tanuja T. Yadav, Mangilal Chouhan and Kapil Kumar*

Volume 24, Issue 4, 2024

Published on: 07 September, 2023

Page: [372 - 390] Pages: 19

DOI: 10.2174/1389557523666230707151553

Price: $65

Abstract

Viruses cause a variety of diseases in the human body. Antiviral agents are used to prevent the production of disease-causing viruses. These agents obstruct and kill the virus's translation and replication. Because viruses share the metabolic processes of the majority of host cells, finding targeted medicines for the virus is difficult. In the ongoing search for better antiviral agents, the USFDA approved EVOTAZ, a new drug discovered for the treatment of Human Immunodeficiency Virus (HIV). It is a once-daily (OD) fixed-dose combination of Cobicistat, a cytochrome P450 (CYP) enzyme inhibitor, and Atazanavir, a protease inhibitor. The combination drug was created in such a way that it can inhibit both CYP enzymes and proteases at the same time, resulting in the virus's death. The drug is not effective in children under the age of 18; however, it is still being studied for various parameters. This review article focuses on EVOTAZ's preclinical and clinical aspects, as well as its efficacy and safety profiles.

« Previous Next »
Graphical Abstract

[1]
Prusoff, W.H.; Lin, T.S.; August, E.M.; Wood, T.G.; Marongiu, M.E. Approaches to antiviral drug development. Yale J. Biol. Med., 1989, 62(2), 215-225.
[PMID: 2773516]
[2]
Granich, R.; Williams, B. HIV treatment: Time to lean forward. Lancet, 2016, 387(10013), 27.
[http://dx.doi.org/10.1016/S0140-6736(15)01293-3] [PMID: 26766341]
[3]
Long H, Aids. Med. Care, 2012, 916, 874-7720.
[4]
Razonable, R.R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc., 2011, 86(10), 1009-1026.
[http://dx.doi.org/10.4065/mcp.2011.0309] [PMID: 21964179]
[5]
Narang, B.; Grewal, G.; Roy, S.; Bariwal, J.; Gupta, M.; Rawal, R. A novel integrase targeting agent to explore the future prospective of HIV eradication. Dolutegravir. Curr. HIV Res., 2014, 12(5), 325-338.
[http://dx.doi.org/10.2174/1570162X12666140807150753] [PMID: 25106411]
[6]
Gallo, R.C.; Montagnier, L. The discovery of HIV as the cause of AIDS. N. Engl. J. Med., 2003, 349(24), 2283-2285.
[http://dx.doi.org/10.1056/NEJMp038194] [PMID: 14668451]
[7]
Wei, B.; Han, L.; Abbink, T.E.M.; Groppelli, E.; Lim, D.; Thaker, Y.R.; Gao, W.; Zhai, R.; Wang, J.; Lever, A.; Jolly, C.; Wang, H.; Rudd, C.E. Immune adaptor ADAP in T cells regulates HIV-1 transcription and cell-cell viral spread via different co-receptors. Retrovirology, 2013, 10(1), 101.
[http://dx.doi.org/10.1186/1742-4690-10-101] [PMID: 24047317]
[8]
Broder, S.; Fauci, A.S. Progress in drug therapies for HIV infection. Public Health Rep., 1988, 103(3), 224-229.
[PMID: 3131811]
[9]
Daluge, S.M.; Martin, M.T.; Sickles, B.R.; Livingston, D.A. An efficient, scalable synthesis of the HIV reverse transcriptase inhibitor Ziagen (1592U89). Nucleosides Nucleotides Nucleic Acids, 2000, 19(1-2), 297-327.
[http://dx.doi.org/10.1080/15257770008033011] [PMID: 10772717]
[10]
Perry, C.M.; Noble, S. Didanosine. Drugs, 1999, 58(6), 1099-1135.
[http://dx.doi.org/10.2165/00003495-199958060-00009] [PMID: 10651392]
[11]
Patel, M.; Ko, S.S.; McHugh, R.J., Jr; Markwalder, J.A.; Srivastava, A.S.; Cordova, B.C.; Klabe, R.M.; Erickson-Viitanen, S.; Trainor, G.L.; Seitz, S.P. Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 1999, 9(19), 2805-2810.
[http://dx.doi.org/10.1016/S0960-894X(99)00486-2] [PMID: 10522695]
[12]
Penazzato, M.; Giaquinto, C. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children. Drugs, 2011, 71(16), 2131-2149.
[http://dx.doi.org/10.2165/11597680-000000000-00000] [PMID: 22035514]
[13]
INTELENCE® (etravirine) [Tablets]. Prescribing information. Available From: http://www.fda.gov/cder/foi/label/2008/0221871b1.pdf (Accessed 20 Sept 2008).
[14]
Swainston Harrison, T.; Scott, L.J. Atazanavir. Drugs, 2005, 65(16), 2309-2336.
[http://dx.doi.org/10.2165/00003495-200565160-00010] [PMID: 16266202]
[15]
Prezista. 2008. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf
[16]
Pham, P. Drug profile: fosamprenavir (Lexiva). The Hopkins HIV report: A bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service, 2003, 15(6), 10-11.
[17]
Williams, I.G. Enfuvirtide (Fuzeon): The first fusion inhibitor. Int. J. Clin. Pract., 2003, 57(10), 890-897.
[http://dx.doi.org/10.1111/j.1742-1241.2003.tb10637.x] [PMID: 14712892]
[18]
Kuritzkes, D.; Kar, S.; Kirkpatrick, P. Maraviroc. Nat. Rev. Drug Discov., 2008, 7(1), 15-16.
[http://dx.doi.org/10.1038/nrd2490] [PMID: 19008887]
[19]
Deeks, E.D. Cobicistat: A review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs, 2014, 74(2), 195-206.
[http://dx.doi.org/10.1007/s40265-013-0160-x] [PMID: 24343782]
[20]
Xu, L.; Liu, H.; Murray, B.P.; Callebaut, C.; Lee, M.S.; Hong, A.; Strickley, R.G.; Tsai, L.K.; Stray, K.M.; Wang, Y.; Rhodes, G.R.; Desai, M.C. Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med. Chem. Lett., 2010, 1(5), 209-213.
[http://dx.doi.org/10.1021/ml1000257] [PMID: 24900196]
[21]
Clayden, P.; Collins, S.; Frick, M.; Harrington, M.; Horn, T.; Jefferys, R.; Lessem, E.; McKenna, L.; Swan, T. 2021 Pipeline Report: HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune- Based and Gene Therapies in Development; New York; , 2015.
[22]
Hossain, M.A. New drugs approval. Bangladesh Pharma. J., 2015, 18(1), 83-84.
[http://dx.doi.org/10.3329/bpj.v18i1.23524]
[23]
Podzamczer, D.; Ferrer, E.; Consiglio, E.; Gatell, J.M.; Perez, P.; Perez, J.L.; Luna, E.; González, A.; Pedrol, E.; Lozano, L.; Ocaña, I.; Llibre, J.M.; Casiró, A.; Aranda, M.; Barrufet, P.; Martínez-Lacasa, J.; Miró, J.M.; Badía, X.; Casado, A.; Lupo, S.; Cahn, P.; Maños, M.; Estela, J.; Barberá, M.J.; Santín, M.; Gudiol, F.; Hidalgo, M.; Knobel, H.; Azuaje, C.; Ribera, E.; Roget, M.; Force, L.; Dalmau, D.; Suarez, C. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir. Ther., 2002, 7(2), 81-90.
[http://dx.doi.org/10.1177/135965350200700202] [PMID: 12212928]
[24]
John, M.; McKinnon, E.J.; James, I.R.; Nolan, D.A.; Herrmann, S.E.; Moore, C.B.; White, A.J.; Mallal, S.A. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J. Acquir. Immune Defic. Syndr., 2003, 33(1), 29-33.
[http://dx.doi.org/10.1097/00126334-200305010-00005] [PMID: 12792352]
[25]
Corbett, A.H.; Lim, M.L.; Kashuba, A.D.M. Kaletra (lopinavir/ritonavir). Ann. Pharmacother., 2002, 36(7-8), 1193-1203.
[http://dx.doi.org/10.1345/aph.1A363] [PMID: 12086554]
[26]
Seaton, O.R.A.; Fox, R.; Bodasing, N.; Peters, S.E.; Gourlay, Y. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection. AIDS, 2003, 17(3), 445-447.
[http://dx.doi.org/10.1097/00002030-200302140-00021] [PMID: 12556701]
[27]
Shey, M.; Kongnyuy, E.J.; Shang, J.; Wiysonge, C.S. A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS. Cochrane Database Syst. Rev., 2009.(3), CD005481.
[PMID: 19588374] [http://dx.doi.org/10.1002/14651858.CD005481.pub2.]
[28]
Camp, R. Epzicom Brand Abacavir-Lamivudine QD; Treatment Action Group, 2004.
[29]
James, J.S. FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides. AIDS Treat. News, 2004, (403), 6.
[PMID: 15386855]
[30]
De Clercq, E. From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™. Future Virol., 2006, 1(6), 709-715.
[http://dx.doi.org/10.2217/17460794.1.6.709]
[31]
García-Lerma, J.G.; Cong, M.; Mitchell, J.; Youngpairoj, A.S.; Zheng, Q.; Masciotra, S.; Martin, A.; Kuklenyik, Z.; Holder, A.; Lipscomb, J.; Pau, C.P.; Barr, J.R.; Hanson, D.L.; Otten, R.; Paxton, L.; Folks, T.M.; Heneine, W. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci. Transl. Med., 2010, 2(14), 14ra4.
[http://dx.doi.org/10.1126/scitranslmed.3000391] [PMID: 20371467]
[32]
Deeks, E.D.; Perry, C.M. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): A review of its use in the management of HIV infection. Drugs, 2010, 70(17), 2315-2338.
[http://dx.doi.org/10.2165/11203800-000000000-00000] [PMID: 21080746]
[33]
Kabbara, W.K.; Ramadan, W.H. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. J. Infect. Public Health, 2015, 8(5), 409-417.
[http://dx.doi.org/10.1016/j.jiph.2015.04.020] [PMID: 26001757]
[34]
Bernardini, C.; Maggiolo, F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection. Patient Prefer. Adherence, 2013, 7, 531-542.
[PMID: 23814462]
[35]
Breeze, S. Novel HIV-1 treatment Stribild™ gains regulatory approval. Expert Rev. Clin. Pharmacol., 2012, 5(6), 613.
[PMID: 23234321]
[36]
Olin, J.L.; Spooner, L.M.; Klibanov, O.M. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann. Pharmacother., 2012, 46(12), 1671-1677.
[http://dx.doi.org/10.1345/aph.1R468] [PMID: 23136357]
[37]
McKeage, K.; Perry, C.M.; Keam, S.J. Darunavir. Drugs, 2009, 69(4), 477-503.
[http://dx.doi.org/10.2165/00003495-200969040-00007] [PMID: 19323590]
[38]
Astuti, N.; Maggiolo, F. Single-tablet regimens in HIV therapy. Infect. Dis. Ther., 2014, 3(1), 1-17.
[http://dx.doi.org/10.1007/s40121-014-0024-z] [PMID: 25134808]
[39]
DeJesus, E.; Rockstroh, J.K.; Henry, K.; Molina, J.M.; Gathe, J.; Ramanathan, S.; Wei, X.; Yale, K.; Szwarcberg, J.; White, K.; Cheng, A.K.; Kearney, B.P. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet, 2012, 379(9835), 2429-2438.
[http://dx.doi.org/10.1016/S0140-6736(12)60918-0] [PMID: 22748590]
[40]
Gunawardana, M.; Remedios-Chan, M.; Miller, C.S.; Fanter, R.; Yang, F.; Marzinke, M.A.; Hendrix, C.W.; Beliveau, M.; Moss, J.A.; Smith, T.J.; Baum, M.M. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob. Agents Chemother., 2015, 59(7), 3913-3919.
[http://dx.doi.org/10.1128/AAC.00656-15] [PMID: 25896688]
[41]
Fellner, C. pharmaceutical approval update. P&T, 2016, 41(4), 220-221.
[PMID: 27069339]
[42]
Kalapila, A.G.; Marrazzo, J. antiretroviral therapy for prevention of human immunodeficiency virus infection. Med. Clin. North Am., 2016, 100(4), 927-950.
[http://dx.doi.org/10.1016/j.mcna.2016.03.013] [PMID: 27235622]
[43]
Hosein, S.R. Descovy Approved in Canada--Key Information. Canadian AIDS Treatment Information Exchange. 2016. Available From: http://www.thebodypro.com/content/77574/descovy-approved-in-canada--key-information.html (Accessed: May 10, 2016).
[44]
Artacho, M.Á.; Barreiro, P.; Fernández-Montero, J.V. Long-term treatment of patients with HIV-1: The role of atazanavir. HIV AIDS (Auckl.), 2010, 2, 157-166.
[PMID: 22096394]
[45]
Babu, V.V.R.; Sharma, P.K.; Singhvi, I. A new gradient liquid chromatographic method for simultaneous estimation of tenofovir diisoproxil fumarate, cobicistat, emtricitabine and elvitegravir in bulk drug and tablet dosage form. Asian J. Chem., 2014, 26(18), 6233-6237.
[http://dx.doi.org/10.14233/ajchem.2014.17196]
[46]
Ding, H.X.; Leverett, C.A.; Kyne, R.E., Jr; Liu, K.K.C.; Fink, S.J.; Flick, A.C.; O’Donnell, C.J. Synthetic approaches to the 2013 new drugs. Bioorg. Med. Chem., 2015, 23(9), 1895-1922.
[http://dx.doi.org/10.1016/j.bmc.2015.02.056] [PMID: 25797159]
[47]
Han, J.; Konno, H.; Sato, T.; Soloshonok, V.A.; Izawa, K. Tailor-made amino acids in the design of small-molecule blockbuster drugs. Eur. J. Med. Chem., 2021, 220, 113448.
[http://dx.doi.org/10.1016/j.ejmech.2021.113448] [PMID: 33906050]
[48]
Fan, X.; Song, Y.L.; Long, Y.Q. An efficient and practical synthesis of the HIV protease inhibitor Atazanavir via a highly diastereoselective reduction approach. Org. Process Res. Dev., 2008, 12(1), 69-75.
[http://dx.doi.org/10.1021/op7001563]
[49]
von Hentig, N. Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy. HIV AIDS (Auckl.), 2015, 8, 1-16.
[http://dx.doi.org/10.2147/HIV.S70836] [PMID: 26730211]
[50]
Lepist, E.I.; Phan, T.K.; Roy, A.; Tong, L.; MacLennan, K.; Murray, B.; Ray, A.S. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob. Agents Chemother., 2012, 56(10), 5409-5413.
[http://dx.doi.org/10.1128/AAC.01089-12] [PMID: 22850510]
[51]
López-Cortés, L.F. [Pharmacology, pharmacokinetic features and interactions of atazanavir] Enferm. Infecc. Microbiol. Clin., 2008, 26(Suppl. 17), 2-8.
[PMID: 20116610]
[52]
Hossain, M.A.; Tran, T.; Chen, T.; Mikus, G.; Greenblatt, D.J. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. J. Pharm. Pharmacol., 2017, 69(12), 1786-1793.
[http://dx.doi.org/10.1111/jphp.12820] [PMID: 28960344]
[53]
a) Tseng, A.; Hughes, C.A.; Wu, J.; Seet, J.; Phillips, E.J. Cobicistat versus Ritonavir: Similar pharmacokinetic enhancers but some important differences. Ann. Pharmacother., 2017, 51(11), 1008-1022.
[http://dx.doi.org/10.1177/1060028017717018] [PMID: 28627229];
b) EVOTAZ 300 Mg/150 Mg film-coated tablets - Summary of product characteristics. Available From: https://www.medicines.org.uk/emc/medicine/30707 (Accessed 08 Oct 2019). ;
c) Evotaz, FDA Label - Tablet. National Institutes of Health, U.S. Department of Health and Human Services. Available From: https://aidsinfo.nih.gov/drugs/537/evotaz/175/professional (Accessed 08 Oct 2019).
[54]
DeJesus, E.; Rockstroh, J.; Henry, K. Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects. Confe. Retrov. Oppor. Infec, 2012, 3.
[55]
Sax, P.; DeJesus, E.; Mills, A. Elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naïve HIV-1+subjects. Conference on Retroviruses and Opportunistic Infections March 2012Seattle, WA , 2012.
[56]
Margot, N.A.; Kitrinos, K.M.; Fordyce, M.; McCallister, S.; Miller, M.D.; Callebaut, C. Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin. Trials, 2016, 17(2), 78-87.
[http://dx.doi.org/10.1080/15284336.2016.1142731] [PMID: 26892863]
[57]
Colonno, R.; Rose, R.; McLaren, C.; Thiry, A.; Parkin, N.; Friborg, J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis., 2004, 189(10), 1802-1810.
[http://dx.doi.org/10.1086/386291] [PMID: 15122516]
[58]
Brenner, B.G.; Coutsinos, D. The K65R mutation in HIV-1 reverse transcriptase: Genetic barriers, resistance profile and clinical implications. HIV Ther., 2009, 3(6), 583-594.
[http://dx.doi.org/10.2217/hiv.09.40] [PMID: 20190870]
[59]
Achenbach, C.J.; Darin, K.M.; Murphy, R.L.; Katlama, C. Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol., 2011, 6(2), 157-177.
[http://dx.doi.org/10.2217/fvl.10.89] [PMID: 21731578]
[60]
Gianotti, N.; Guffanti, M.; Galli, L.; Margonato, A.; Chiaravalli, G.; Bigoloni, A.; Lazzarin, A.; Castagna, A. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS, 2007, 21(12), 1648-1651.
[http://dx.doi.org/10.1097/QAD.0b013e32826fbc6a] [PMID: 17630564]
[61]
Song, I.; Borland, J.; Chen, S.; Lou, Y.; Peppercorn, A.; Wajima, T.; Min, S.; Piscitelli, S.C. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br. J. Clin. Pharmacol., 2011, 72(1), 103-108.
[http://dx.doi.org/10.1111/j.1365-2125.2011.03947.x] [PMID: 21342217]
[62]
Sevinsky, H.; Tao, X.; Wang, R.; Ravindran, P.; Sims, K.; Xu, X.; Jariwala, N.; Bertz, R. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir. Ther., 2015, 20(5), 493-500.
[http://dx.doi.org/10.3851/IMP2913] [PMID: 25361436]
[63]
Barrail-Tran, A.; Mentré, F.; Cosson, C.; Piketty, C.; Chazallon, C.; Gérard, L.; Girard, P.M.; Taburet, A.M. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob. Agents Chemother., 2010, 54(2), 614-619.
[http://dx.doi.org/10.1128/AAC.00797-09] [PMID: 19995932]
[64]
Wempe, M.F.; Anderson, P.L. Atazanavir metabolism according to CYP3A5 status: An in vitro-in vivo assessment. Drug Metab. Dispos., 2011, 39(3), 522-527.
[http://dx.doi.org/10.1124/dmd.110.036178] [PMID: 21148251]
[65]
Shimpi, S. Bioequivalence Study Recommendation for Atazanavir Sulfate Capsules by US FDA and a Contrary View, 2012, 1, 388.
[66]
Crutchley, R.D.; Cheng, A.; Guduru, R. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV AIDS, 2016, 8(8), 47-65.
[http://dx.doi.org/10.2147/HIV.S99063] [PMID: 27022304]
[67]
a) Pawar, S.; Kumawat, M.K.; Kundu, M.; Kumar, K. Synthetic and medicinal perspective of antileishmanial agents: An overview. J. Mol. Struct., 2023, 1271, 133977.
[http://dx.doi.org/10.1016/j.molstruc.2022.133977];
b) Rathod, B.; Kumar, K. Synthetic and medicinal perspective of 1,2,4-triazole as anticancer agents. Chem. Biodivers., 2022, 19(11), e202200679.
[http://dx.doi.org/10.1002/cbdv.202200679] [PMID: 36226542];
c) Konar, D.; Maru, S.; Kar, S.; Kumar, K. Synthesis and clinical development of Palbociclib: An overview. Med. Chem., 2022, 18(1), 2-25.
[http://dx.doi.org/10.2174/1573406417666201204161243] [PMID: 33280599];
d) Pawar, S.; Kumar, K.; Gupta, M.K.; Rawal, R.K. Synthetic and medicinal perspective of fused-thiazoles as anticancer agents. Anticancer. Agents Med. Chem., 2021, 21(11), 1379-1402.
[http://dx.doi.org/10.2174/1871520620666200728133017] [PMID: 32723259];
e) Kaur, R.; Kumar, K. Synthetic and medicinal perspective of quinolines as antiviral agents. Eur. J. Med. Chem., 2021, 215, 113220-113258.
[http://dx.doi.org/10.1016/j.ejmech.2021.113220] [PMID: 33609889];
f) Kapoor, Y.; Kumar, K. Structural and clinical impact of anti-allergy agents: An overview. Bioorg. Chem., 2020, 94, 103351-103375.
[http://dx.doi.org/10.1016/j.bioorg.2019.103351] [PMID: 31668464];
g) Kaur, R.; Manjal, S.K.; Rawal, R.K.; Kumar, K. Recent synthetic and medicinal perspectives of tryptanthrin. Bioorg. Med. Chem., 2017, 25(17), 4533-4552.
[http://dx.doi.org/10.1016/j.bmc.2017.07.003] [PMID: 28720329];
h) Kaur Manjal, S.; Kaur, R.; Bhatia, R.; Kumar, K.; Singh, V.; Shankar, R.; Kaur, R.; Rawal, R.K. Synthetic and medicinal perspective of thiazolidinones: A review. Bioorg. Chem., 2017, 75, 406-423.
[http://dx.doi.org/10.1016/j.bioorg.2017.10.014] [PMID: 29102723];
i) Kaur, R.; Chaudhary, S.; Kumar, K.; Gupta, M.K.; Rawal, R.K. Recent synthetic and medicinal perspectives of dihydropyrimidinones: A review. Eur. J. Med. Chem., 2017, 132, 108-134.
[http://dx.doi.org/10.1016/j.ejmech.2017.03.025] [PMID: 28342939];
j) Kumar, B.; Singh, V.; Shankar, R.; Kumar, K.; Rawal, R. Synthetic and medicinal prospective of structurally modified curcumins. Curr. Top. Med. Chem., 2016, 17(2), 148-161.
[http://dx.doi.org/10.2174/1568026616666160605050052] [PMID: 27280465];
k) Mittal, M.; Kumar, K.; Anghore, D.; Rawal, R.K. ICP-MS: Analytical method for identification and detection of elemental impurities. Curr. Drug Discov. Technol., 2017, 14(2), 106-120.
[http://dx.doi.org/10.2174/1570163813666161221141402] [PMID: 28003007];
l) Talwan, P.; Choudhary, S.; Kumar, K.; Rawal, R.K. Chemical and medicinal versatility of substituted 1, 4-dihydropyridines. Curr. Bioact. Compd., 2017, 13, 109-120.
[http://dx.doi.org/10.2174/1573407212666160607090202]
[68]
Puri, S.; Ahmad, I.; Patel, H.; Kumar, K.; Juvale, K. Evaluation of oxindole derivatives as a potential anticancer agent against breast carcinoma cells: In vitro, in silico and molecular docking study. Toxicol in vitro. 2023, 86, 105517.;
b) Kumawat, K; Kaur, R.; Kumar, K. In-silico prediction of novel fused quinazoline based topoisomerase inhibitors as anticancer agents. Med. Chem., 2023, 19, 431-444.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy